Protagonist Therapeutics, Inc. — FY2018 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2018; filed March 12, 2019. The filing is an annual report rather than a standalone fourth-quarter filing. Protagonist is a clinical-stage biopharmaceutical company with no approved products or product sales, developing peptide-based therapies in hematology and gastroenterology.
Business Context and Pipeline
- PTG-300: Injectable hepcidin mimetic for beta-thalassemia and other iron-dysregulation disorders. The company filed a U.S. IND and initiated enrollment in a global Phase 2 beta-thalassemia study during 2018; patient dosing began in Q1 2019. FDA Fast Track and FDA/EU orphan drug designations were in place.
- PTG-200: Oral, GI-restricted IL-23 receptor antagonist being co-developed with Janssen for inflammatory bowel disease. Phase 1 in 80 healthy volunteers was completed in 2018, and Janssen was expected to file a U.S. IND in the first half of 2019.
- PN-943: Oral, GI-restricted alpha-4-beta-7 integrin antagonist. A Phase 1 study began in late 2018, with results expected in the first half of 2019 and a potential UC Phase 2 study targeted for the first half of 2020.
- PTG-100: Global Phase 2 UC trial was discontinued in March 2018 for futility after an interim analysis. A later blinded endoscopy re-read identified efficacy signals, which management attributed to human error and an unusually high placebo effect in the original reads. The company replaced PTG-100 with PN-943.
Financial Performance and Position
| Metric | FY2018 | FY2017 | Change |
|---|---|---|---|
| License and collaboration revenue | $30.9 million | $20.1 million | Up 54% |
| Research and development expense | $59.5 million | $46.2 million | Up 29% |
| General and administrative expense | $13.7 million | $11.8 million | Up 16% |
| Loss from operations | $42.3 million | $37.9 million | Loss increased $4.4 million |
| Interest income | $2.5 million | $0.9 million | Up 171% |
| Income tax benefit | $0.8 million | None | New in 2018 |
| Net loss | $38.9 million | $37.0 million | Loss increased $2.0 million |
| Basic and diluted net loss per share | $1.74 loss | $2.09 loss | Improved due primarily to higher share count |
- Revenue was entirely license, collaboration and related services revenue; the company had no product revenue.
- Revenue represented approximately 42% of operating expenses. On a reported basis, net loss was approximately 126% of revenue, although the revenue consisted primarily of collaboration accounting and was not recurring product sales.
- FY2018 research and development spending included $14.3 million for PTG-300, $16.1 million for PTG-200, $20.4 million for PTG-100, $0.5 million for PN-943 and $9.8 million of preclinical and discovery research, before grants and incentives.
- Cash used in operating activities was $49.9 million, compared with $3.9 million of operating cash flow provided in 2017. The decline primarily reflected a $23.5 million reduction in deferred revenue related to Janssen.
- Cash, cash equivalents and available-for-sale securities totaled $128.9 million at year-end, compared with $155.5 million at year-end 2017. Working capital was $111.3 million.
- Total assets were $139.5 million and stockholders’ equity was $112.5 million. The company reported no outstanding debt or credit facility.
- FY2018 financing cash flow was $24.1 million, including $21.7 million of net proceeds from a private placement and warrants, $1.5 million from an ATM offering and $0.9 million from employee equity activity.
Material Changes Versus FY2017
- License and collaboration revenue increased by $10.9 million as the company recognized additional Janssen-related deferred revenue and cost-sharing revenue tied to PTG-200 Phase 1 and Phase 2a activities.
- R&D spending increased $13.3 million, driven mainly by increased PTG-200 and PTG-300 clinical activity and the PN-943 Phase 1 program, partly offset by lower PTG-100 and preclinical spending.
- Operating cash flow shifted from a $3.9 million inflow to a $49.9 million outflow as deferred revenue was recognized and clinical spending increased.
- Cash and investments declined $26.6 million despite $24.1 million of financing proceeds, reflecting operating cash burn and changes in working capital.
- The company raised $21.7 million net in an August 2018 private placement of 2.75 million shares and issued warrants for 2.75 million additional shares at exercise prices of $10.00 and $15.00. None had been exercised at year-end.
- In December 2018, the company exchanged 1.0 million common shares for pre-funded warrants exercisable at $0.00001 per share, subject to a 9.99% beneficial ownership limitation.
Outlook, Agreements, Risks and Unusual Items
- Management believed year-end cash, cash equivalents and available-for-sale securities would fund operations for at least the next 12 months, but stated that additional substantial capital would be required for pivotal trials and commercialization.
- The Janssen agreement provided a $25.0 million potential payment upon IND filing, up to $325.0 million of potential opt-in payments, up to $590.0 million of additional development, regulatory and sales milestones, and tiered royalties ranging from 10% to the mid-teens on worldwide net sales. None of the milestone or royalty revenue had been recognized as of year-end.
- Janssen may elect not to continue PTG-200 development after specified Phase 2 stages or may terminate the agreement. Termination would eliminate potential future payments and could require Protagonist to fund further PTG-200 development.
- The company expects continued losses and increasing R&D expenses. Product approval, commercialization and profitability remain uncertain.
- Clinical development risks include trial delays, enrollment challenges, safety or efficacy failures, regulatory rejection, manufacturing dependence and possible adverse interpretation of clinical data.
- The company relies on third-party contract research organizations and manufacturers and owns no manufacturing facilities. Clinical and commercial supply interruptions could delay development.
- Potential contractual obligations included $11.2 million of operating lease payments through 2024 and beyond. Additional development, milestone and royalty obligations were not determinable and were excluded from the contractual obligations table.
- The company recognized a $0.8 million income tax benefit from releasing a valuation allowance related to its Australian subsidiary, while U.S. deferred tax assets remained subject to a valuation allowance. Federal net operating loss carryforwards were approximately $109.1 million but may be limited by ownership changes.
- The PTG-200 patent litigation filed by Medical Diagnostic Laboratories was dismissed in the company’s favor in February 2018; judgment ending the case was issued in March 2018, and no appeal was filed.
Investor Verification Checklist
- Verify the timing and terms of Janssen’s expected PTG-200 IND filing and whether the $25.0 million payment was subsequently earned.
- Track Phase 2 PTG-300 enrollment, safety, hemoglobin and transfusion-reduction data, and the planned second-indication study.
- Assess PN-943 Phase 1 results and whether the company filed an IND and initiated the anticipated UC Phase 2 program.
- Reconcile collaboration revenue with cash receipts, deferred revenue, cost-sharing payments and the estimated $60.7 million Janssen transaction price.
- Monitor cash burn, remaining ATM capacity of $48.3 million at year-end, additional financing needs and potential dilution from outstanding warrants and equity awards.
- Evaluate the impact of discontinuing PTG-100, including continuing wind-down costs and the reliability of the corrected efficacy analyses.
- Review the company’s dependence on third-party manufacturers, CROs and Janssen, as well as patent protection, regulatory milestones and competing IBD and beta-thalassemia therapies.